AnesthesiaNCT06709066
Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy
A study testing mivacurium chloride and succinylcholine in people with Anesthesia and Bronchoscopy, run by Peng Liang.
Trial summary
The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Anesthesia, Bronchoscopy, Muscle Relaxants
- What is being tested?
- mivacurium chloride and succinylcholine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- No sites listed yet
- Study dates
- 20 Nov 2024to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.
- Aged between 18 and 60 years.
- Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.
- Patients voluntarily participate and sign an informed consent form.
Who cannot join
- Patients with known allergies to any of the drugs involved in the study.
- Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.
- Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.
- Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.
- Patients who have used medications affecting neuromuscular transmission function before the procedure.
- Pregnant or breastfeeding patients.
- Patients who have experienced extensive burns, acid-base imbalance, or electrolyte disturbances within the past six months.
- Patients known or suspected to be homozygous for the atypical gene for plasma cholinesterase.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:
- Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine?
- How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.
Read more
Participants will:
- Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy.
- Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure.
- Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.
- Conditions
- Anesthesia, Bronchoscopy, Muscle Relaxants
- Being tested
- mivacurium chloride, succinylcholine
- Medical subject headings
- Muscle Hypotonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mivacurium chlorideDrug
mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
succinylcholineDrug
succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
| Study group | Role | What they receive |
|---|---|---|
| mivacurium chloride | Experimental | mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion Receives: Drug: mivacurium chloride |
| succinylcholine | Active comparator | succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) Receives: Drug: succinylcholine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of spontaneous breathing recovery
The rate of spontaneous breathing recovery after discontinuation of mivacurium chloride and succinylcholine during bronchoscopy.
Measured: Within 15 minutes after the completion of bronchoscopy.
Secondary outcomes (6)
Recovery time of spontaneous breathing
Comparison of recovery times (minutes) for spontaneous breathing between mivacurium chloride and succinylcholine groups. Spontaneous breathing recovery is defined as achieving a tidal volume of 5 ml/kg and a respiratory rate of 12 breaths per minute.
Measured: From the end of bronchoscopy until spontaneous breathing, assessed up to 15 minutes post-procedure.
Recovery time of consciousness
Comparison of recovery times (minutes) for consciousness recovery. Consciousness recovery is defined as the ability to open eyes upon verbal command or when called by name.
Measured: From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
Laryngeal mask airway (LMA) removal time
Comparison of time to remove laryngeal mask airway (LMA) between mivacurium chloride and succinylcholine groups.
Measured: From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
Mean pulse pressure at different stages
Blood pressure measurements should be taken at 1-minute intervals during the induction phase (pre-LMA insertion), until the LMA is inserted. For the pre-induction phase, post-LMA insertion, surgery start, surgery end, and post-LMA removal, blood pressure should be measured every 3 minutes, with recordings taken for a total of 3 minutes at each stage. The average blood pressure (mmHg) for each stage was calculated using the values recorded during that stage for both the mivacurium chloride and succinylcholine groups.
Measured: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Oxygen saturation (%) recorded at different stages
Oxygen saturation (%) recorded for both mivacurium chloride and succinylcholine groups at different stages.
Measured: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Heart rate recorded at different stages
Heart rate recorded (beats per minute) at different stages for both mivacurium chloride and succinylcholine groups.
Measured: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2024
- Study start20 Nov 2024 (estimated)
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AnesthesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peng Liang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Peng Liang, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06709066
- Sponsor's protocol ID
- 2024No.1625
- Other IDs
- ChiCTR
- Status last verified
- Nov 2024
- First submitted
- 17 Oct 2024
- Last updated
- 29 Nov 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhang X, Xu Y, Li J, Xi Y, Xu Z, Liang P. Effect and safety of mivacurium chloride and succinylcholine for bronchoscopy: study protocol for a single-center, randomized, non-inferiority, and positive-controlled clinical trial. Trials. 2026 Jan 22;27(1):137. doi: 10.1186/s13063-026-09463-3.
PubMed 41566470
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy
- ClinicalTrials.gov ID
- NCT06709066
- Acronym / sponsor ID
- 2024No.1625
- Conditions
- Anesthesia, Bronchoscopy, Muscle Relaxants
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Peng LiangUniversity, hospital or other
- Study start
- 20 Nov 2024 (estimated)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 29 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:
- Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine?
- How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.
Participants will:
- Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy.
- Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure.
- Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| mivacurium chloride | Experimental | Drug: mivacurium chloridemivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion |
| succinylcholine | Active comparator | Drug: succinylcholinesuccinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.
- Aged between 18 and 60 years.
- Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.
- Patients voluntarily participate and sign an informed consent form.
Key exclusion criteria (8 listed)
- Patients with known allergies to any of the drugs involved in the study.
- Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.
- Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.
- Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.
- Patients who have used medications affecting neuromuscular transmission function before the procedure.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mivacurium chloridemivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion | Drug | mivacurium chloride |
| succinylcholinesuccinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) | Drug | succinylcholine |
Primary outcome
Rate of spontaneous breathing recovery
Time frame: Within 15 minutes after the completion of bronchoscopy.
The rate of spontaneous breathing recovery after discontinuation of mivacurium chloride and succinylcholine during bronchoscopy.
6 secondary outcomes
Recovery time of spontaneous breathing
Time frame: From the end of bronchoscopy until spontaneous breathing, assessed up to 15 minutes post-procedure.
Recovery time of consciousness
Time frame: From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
Laryngeal mask airway (LMA) removal time
Time frame: From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
Mean pulse pressure at different stages
Time frame: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Oxygen saturation (%) recorded at different stages
Time frame: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Heart rate recorded at different stages
Time frame: 3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2024.
- Derived from this study: PubMed 41566470Zhang X, Xu Y, Li J, Xi Y, Xu Z, Liang P. Effect and safety of mivacurium chloride and succinylcholine for bronchoscopy: study protocol for a single-center, randomized, non-inferiority, and positive-controlled clinical trial. Trials. 2026 Jan 22;27(1):137. doi: 10.1186/s13063-026-09463-3.
- Individual participant dataSharing planned: No
Related trials for Anesthesia
Not yet recruitingObservational study
"Comparison of Oxygen Reserve Index (ORI), End-Tidal Oxygen, and Time-Based Preoxygenation Targets With Arterial Blood Gas During Preoxygenation
Preoxygenation Adequacy Assessed by Oxygen Reserve Index, End-tidal Oxygen and Arterial Blood Gas
RecruitingObservational study
Comparison of Hemodynamic Responses During Anesthesia Induction Using Eleveld and Schnider
Spinal (Fusion) Surgery, Total Intravenous Anesthesia
Not yet recruiting
A Randomized Controlled SaCo-VLM Trial
General Anaesthesia Using Supraglotic Airway
Not yet recruiting
Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography
Deep Sedation, Endoscopic Retrograde Cholangiopancreatography
RecruitingPhase 4
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing mivacurium chloride and succinylcholine in people with Anesthesia and Bronchoscopy, run by Peng Liang.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Peng Liang (18980608961, liangpengwch@scu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of spontaneous breathing recovery (time frame: Within 15 minutes after the completion of bronchoscopy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06709066, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2024.